Myelofibrosis (MF) is a rare and chronic bone marrow disorder characterized by the progressive replacement of normal bone marrow tissue with fibrous scar tissue. This fibrosis scar tissue disrupts the normal production of blood cells in the bone marrow, leading to various complications. This activity will assist clinicians in providing patient-centered care for patients with MF. 

Learners will gain a greater understanding of pathophysiologic mechanisms of MF, the impact of this condition on patients’ QoL, limitations of current therapies, the latest data on emerging treatment options, and how to apply this information into practice with a patient-centric approach.

This course consists of three modules. Physicians who complete all three modules may earn a maximum of 1.0 AMA PRA Category 1 Credit™ and ABIM Maintenance of Certification (MOC) point

Target Audience

Hematologists, hematologists/oncologists, hematology/oncology nurse practitioners, physician associates, and other health care professionals involved in the treatment and management of patients with myelofibrosis.

Learning Objectives

Upon completion of this activity, the learners should be able to:

• Explain the pathophysiologic mechanisms involved in the development of MF and progression of the disease 

• Describe the burden of disease and impact on quality of life for patients with MF and as a consequence of current treatments 

• Identify current and future goals for managing MF based on therapeutic targets for improved overall survival 

• Compare and contrast clinical data on new and emerging agents for myelofibrosis with a focus on improving QoL 

• Identify strategies to prevent, monitor, and manage treatment-related adverse effects 

• Recognize approaches to ensure shared decision-making and equitable care with patients

Accreditation Type

This course consists of three modules. Physicians who complete all three modules may earn a maximum of 1.0 AMA PRA Category 1 Credit™ and ABIM Maintenance of Certification (MOC) point